{"id":"W4379338875","doi":"10.1200/jco.2023.41.16_suppl.10016","title":"A phase 3 trial of inotuzumab ozogamicin for high-risk B-ALL: Second safety phase results from Children’s Oncology Group AALL1732.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health","keywords":"Medicine; Internal medicine; Refractory (planetary science); Interim analysis; CD22; Gastroenterology; Minimal residual disease; Surgery; Chemotherapy; Randomized controlled trial; Leukemia; Lymphoma; CD20","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.01302725,0.0003492611,0.004066844,0.0005925817,0.00009391162,0.00001310932,0.0006538643,0.001414397,0.0003776393],"category_scores_gemma":[0.03615077,0.0002620931,0.001226941,0.0004768828,0.0006556655,0.0001759065,0.0002484816,0.002368338,0.00007316865],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001643261,"about_ca_system_score_gemma":0.008562448,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003689738,"about_ca_topic_score_gemma":0.0002824399,"domain_scores_codex":[0.9883837,0.001684935,0.007550658,0.0006365454,0.0009774127,0.0007667851],"domain_scores_gemma":[0.9588165,0.03318165,0.005585534,0.0006305816,0.0008751027,0.0009106497],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6861229,0.01421365,0.0003210036,0.00003286369,0.002225482,0.001075556,0.0002878264,0.0000147779,0.001251425,0.0001203344,0.0597086,0.2346256],"study_design_scores_gemma":[0.6970455,0.1887375,0.005999174,0.0001005689,0.001412531,0.0001969907,0.0001381736,0.001234294,0.0004753013,0.00117008,0.1033069,0.0001829748],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.983523,0.00008993503,0.001426666,0.007126999,0.003676601,0.001644518,0.001705323,0.0000457022,0.0007613179],"genre_scores_gemma":[0.9801257,0.001412481,0.008137962,0.001537909,0.007633158,0.0000304332,0.0005321961,0.00007433647,0.000515885],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2344426,"threshold_uncertainty_score":0.9999831,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1179596185708861,"score_gpt":0.4957514350111695,"score_spread":0.3777918164402835,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}